Tavira Therapeutics: Funding, Investors & Team (Sep 2026)
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding specific molecules to AAV vectors, the company is able to develop more precise and safer gene therapies, a major breakthrough in the industry. Established as a spin-off from KU Leuven and Trellis, Tavira is utilizing cutting-edge research to enhance gene therapy through modular AAV capsid technologies.
Tavira Therapeutics has raised $360k across 1 funding round on record, the most recent an undisclosed round of $360k announced in Feb 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tavira Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Tavira Therapeutics Funding Rounds
Tavira Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Tavira Therapeutics Funding Compared to Other Biotechnology Startups
Tavira Therapeutics' latest round of $360k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tavira Therapeutics in Biotechnology and Teuven
Companies Similar to Tavira Therapeutics
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global…
Tavira Therapeutics Funding FAQs
What does Tavira Therapeutics do?
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding specific molecules to AAV vectors, the company is able to develop more precise and safer gene therapies, a major breakthrough in the industry. Established as a spin-off from KU Leuven and Trellis, Tavira is utilizing cutting-edge research to enhance gene therapy through modular AAV capsid technologies.
How much funding has Tavira Therapeutics raised?
Tavira Therapeutics has raised $360k across 1 round on record. The most recent is an undisclosed round of $360k announced in Feb 2025.
When did Tavira Therapeutics last raise funding?
Tavira Therapeutics' most recent funding round on record is an undisclosed round of $360k, announced in Feb 2025.
Who founded Tavira Therapeutics?
FundedIQ lists Benjamien Moeyaert (Founder) at Tavira Therapeutics.
Where is Tavira Therapeutics headquartered?
Tavira Therapeutics is based in Teuven, Limburg, Belgium.
How many employees does Tavira Therapeutics have?
Tavira Therapeutics is in the 1-10 employee band.
How does Tavira Therapeutics' funding compare to other Biotechnology startups?
Tavira Therapeutics' latest round of $360k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Tavira Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tavira Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.